Innocan Pharma and Health Investment Group SA sign exclusive distribution agreement for Poland

0

News and research before you hear about it on CNBC and others. Claim your 1-week free trial for StreetInsider Premium here.


Herzliya, Israel and Calgary, Alberta – (Newsfile Corp. – July 1, 2021) – Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INPF) (the “Company” or “Innocan”), is pleased to announce that it has signed an exclusive distribution agreement with Health Investment Group SA (“HIG”) for HIG to distribute Innocan’s SHIR and Relief & Go brands in Poland. The Polish domestic market for cosmetics is growing rapidly within the European economy.

Figure 1: Shir by Innocan Pharma

To view an improved version of Figure 1, please visit:
https://orders.newsfilecorp.com/files/6922/89207_241c9d95a4ce1b63_002full.jpg

In 2020, the Polish luxury cosmetics and perfumes market was worth 185 million euros. By 2025, the value of this sector is expected to exceed 221 million euros, according to Statista. In addition, Euromonitor, a well-known market research group, recently reported that the Polish market for hemp and CBD products is expected to reach a total value of € 1 billion by 2025.

About Health Investment Group SA

Health Investment Group SA is part of the IPS Holding group and is responsible for the international JUST BUY IT project. HIG is responsible for the group’s strategic initiatives and is currently working with around 30 international brands for exclusive distribution in Poland. HIG’s customers include the large pharmaceutical wholesaler TRAMCO which supplies smaller wholesalers, hundreds of pharmacies and hospitals across the country. In May, HIG participated in three product categories in the most prestigious research in Poland, in which the jury of members of the board of directors, purchasing and marketing directors of the largest retail chains, such as Lidl, Biedronka, Kaufland, SPAR, Shell or Lotos. .

Thanks to specialists selected to measure, HIG collaborates with related companies of the IPS Holding group to create an international distribution network of exclusive brands. The main field of activity is the production and distribution of premium products, including emerging CBD products and applications.

Marius Gorsky, Managing Director of IPS Holding Group, said: “Health Investment Group SA is delighted to add the Shir & Relief & Go brands to its existing distribution channels among pharmacies, pharmaceutical wholesalers and some retail chains. Poland.

Iris Binkovich, CEO of InnoCan Pharma: “We are honored to have added another leading European market partner such as Health Investment Group as a market partner in Poland.

About Innocan

Innocan Israel, a wholly owned subsidiary of the Company, is a pharmaceutical technology company focused on the development of multiple drug delivery platforms containing CBD. Innocan Israel and Ramot at Tel Aviv University are collaborating on a revolutionary new exosome-based technology that targets both central nervous system (CNS) indications and the Corona Covid-19 virus using CBD. CBD-laden exosomes have the potential to aid in the recovery of infected lung cells. This product, which should be administered by inhalation, will be tested against various lung infections.

Innocan Israel has signed a worldwide exclusive license agreement with Yissum, the commercial arm of the Hebrew University of Jerusalem, to develop a unique controlled-release liposome-based CBD drug delivery platform for injection. Innocan Israel plans, in collaboration with Prof. Berenholtz, head of the membranes and liposome research laboratory at the Hebrew University of Jerusalem, to test the liposome platform on several potential indications. Innocan Israel is also working on a skin product that integrates CBD with other pharmaceutical ingredients as well as the development and sale of pharmaceutical products integrated with CBD, including, but not limited to, topical treatments for symptom relief. psoriasis as well as the treatment of muscle pain and rheumatic pain. The founders and executives of Innocan Israel each have successful business backgrounds in the pharmaceutical and technology sectors in Israel and around the world.

For more information, please contact:

Innocan Pharma Corporation
Iris Binkovich, CEO
+ 972-54-3012842
info@innocanpharma.com

RI: Lytham Partners, LLC
Ben Shamsian CPA | Vice president
Direct: 646-829-9701
Cell: 516-652-9004
shamsian@lythampartners.com

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATORY SERVICE PROVIDER HAS REVIEWED OR ACCEPTED RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS COMMUNICATION.

Caution regarding forward-looking information

Certain information contained in this press release, including, but not limited to, information regarding research and development, collaborations, the potential to treat conditions and other therapeutic effects resulting from research activities and / or the Company’s products, required regulatory approvals, size of the cosmetics and perfumes market in Poland, size of the CBD and hemp market, and timing of market entry, potential sales resulting from the distribution agreement is forward-looking information within the meaning of applicable securities laws. By their nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan’s control. The forward-looking information contained in this press release is based on certain key expectations and assumptions made by Innocan, including expectations and assumptions regarding the anticipated benefits of the products, the satisfaction of regulatory requirements in various jurisdictions and the satisfactory completion of production and distribution required. .

Forward-looking information is subject to various risks and uncertainties which could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this press release. Principal risks and uncertainties include, but are not limited to: general economic, market and business conditions, global and local (national); government and regulatory requirements and actions of government authorities; and relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks inherent in the nature of product distribution, including import / export issues and failure to obtain required regulatory and other approvals (or to do so in a timely manner) and availability on each site. input and finished product market. some products. The expected timeframe for market entry may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for more time to enter into and / or meet manufacturing and service agreements. distribution. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this press release regarding the timing of the commencement of distribution of the product. A full discussion of other risks that impact Innocan can also be found in Innocan’s public reports and filings which are available under Innocan’s profile at www.sedar.com.

Readers are cautioned not to place undue reliance on forward-looking information, as actual results may differ materially from forward-looking information. Innocan does not undertake to update, correct or revise forward-looking information as a result of new information, future events or otherwise, except as required by applicable law.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/89207

Share.

Leave A Reply